Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 211 to 220 of 2605 total matches.
Corrections: Drugs for Diabetes & Another Insulin Glargine (Basaglar) for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
Corrections: Drugs for Diabetes & Another Insulin Glargine (Basaglar) for Diabetes ...
Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9)In the 4th paragraph of the GLP-1 receptor agonists section, we mistakenly stated that Xultophy 100/3.6 is a combination of insulin degludec and albiglutide; Xultophy 100/3.6 is a combination of insulin degludec and liraglutide.Another Insulin Glargine (Basaglar) for Diabetes (Med Lett Drugs Ther 2017; 59:3)In the Dosage and Administration section, we removed the word "syringe" to describe Basaglar's KwikPen device. Basaglar is not available as a prefilled syringe; it is only available as a KwikPen.Download complete U.S. English...
Comparison Table: Some Topical Drugs for Rosacea (online only)
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
Comparison Table: Some Topical Drugs for Rosacea (online only) ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2024 Feb 5;66(1695):e22 doi:10.58347/tml.2024.1695c | Show Introduction Hide Introduction
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only) ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only) ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only) ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721b | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only) ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2 doi:10.58347/tml.2023.1678c | Show Introduction Hide Introduction
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors ...
Opioids delay gastric emptying and the absorption of many
oral drugs, including the P2Y12 inhibitors clopidogrel (Plavix,
and generics), prasugrel (Effient, and generics), and ticagrelor
(Brilinta), which are commonly used for initial treatment of
acute coronary syndrome (ACS). An article in our February 25,
2019 issue reviewed studies showing that coadministration
of opioids delayed and decreased absorption of oral P2Y12
inhibitors and increased platelet reactivity. Recently published
clinical outcomes data may add to these concerns.
Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta) ...
The FDA has approved two new drugs for sickle cell
disease: crizanlizumab-tmca (Adakveo – Novartis), an
IV P-selectin blocker, and voxelotor (Oxbryta – GBT),
an oral hemoglobin S (HbS) polymerization inhibitor.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa) ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only) ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction